Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Evogene (EVGN) over the last 15 years, with Q3 2025 value amounting to $5.6 million.

  • Evogene's Cash & Equivalents fell 5028.72% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 5028.72%. This contributed to the annual value of $15.3 million for FY2024, which is 2633.83% down from last year.
  • According to the latest figures from Q3 2025, Evogene's Cash & Equivalents is $5.6 million, which was down 5028.72% from $15.3 million recorded in Q2 2025.
  • Evogene's Cash & Equivalents' 5-year high stood at $42.8 million during Q2 2021, with a 5-year trough of $5.6 million in Q3 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $23.0 million (2023), whereas its average is $23.4 million.
  • Per our database at Business Quant, Evogene's Cash & Equivalents plummeted by 5859.28% in 2024 and then skyrocketed by 6133.49% in 2025.
  • Over the past 5 years, Evogene's Cash & Equivalents (Quarter) stood at $32.3 million in 2021, then dropped by 10.35% to $29.0 million in 2022, then decreased by 28.32% to $20.8 million in 2023, then dropped by 26.34% to $15.3 million in 2024, then plummeted by 63.23% to $5.6 million in 2025.
  • Its Cash & Equivalents stands at $5.6 million for Q3 2025, versus $15.3 million for Q2 2025 and $7.5 million for Q1 2025.